News
Flordis Launches Ellura
Flordis Natural Medicines has enlisted strong support for the launch of its new Ellura cranberry- based supplement, in the form of Dr Amy Howell, Associate Research Scientist at Rutgers University in the USA, who visited Australia last week highlighting clinical evidence for the product and its action to promote urinary tract health.
Howell, who’s pictured above centre with Nick Burgess and Liisa Lewis from Flordis, has led studies which have shown that Ellura has a dose-dependent and fast acting effect, significantly increasing bacterial anti-adhesion activity in urine samples collected from subjects who took Ellura versus a placebo in a randomised double- blind clinical trial.
Ellura is a unique extract from American cranberries (vaccinium macrocarpon) which has been standardised so that each capsule provides the recommended dose of 36mg of proanthocyanidins (PACs) - equivalent to the juice of 70g of fresh cranberry fruit. “Cranberries play an important role in preventing antibiotic resistant bacteria from colonising the urinary tract, and therefore... may help to reduce the frequency of recurrent cystitis,” Howell said.
She said the efficacy of the specific 36mg dosage had been evaluated in several trials and is “important in distinguishing Ellura from other cranberry formulations”.
Ellura is now available in community pharmacies and select health food stores nationally.
Learn more on Flordis products with the education modules below.
Source: pharmacydaily.com.au, Tuesday 25 Feb 2014
